‌

US Patent 11560371 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Patent 11560371 was granted and assigned to Celgene on January, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Celgene

Current Assignee

Celgene

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11560371

Date of Patent

January 24, 2023

Patent Application Number

17356283

Date Filed

June 23, 2021

Patent Citations

‌

US Patent 11149007 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

‌

US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation

‌

US Patent 11325889 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Patent Citations Received

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11560371 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API